中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2014年
5期
574-576
,共3页
刘泽军%李晚珍%曾艺文%刘卫
劉澤軍%李晚珍%曾藝文%劉衛
류택군%리만진%증예문%류위
原发性高血压%早期肾损害%血管指数%阻力指数%丹参川芎嗪%前列地尔
原髮性高血壓%早期腎損害%血管指數%阻力指數%丹參川芎嗪%前列地爾
원발성고혈압%조기신손해%혈관지수%조력지수%단삼천궁진%전렬지이
Primary hypertension%Early renal damage%Vascular index%Resistance index%Danshen Chuanxiongqin Injection%Alprostadil
目的:探讨丹参川芎嗪联合前列地尔对原发性高血压患者早期肾损害的疗效。方法选择2011年12月至2013年11月在肇庆医专附属医院心内科住院的轻、中度原发性高血压伴早期肾损害患者120例,其中男性62例,女性58例,年龄33~78岁。所有患者随机分为A组,B组,C组,每组40例。所有患者均予缬沙坦降压治疗,A组加用丹参川芎嗪注射液,B组加用前列地尔注射液,C组同时给予丹参川芎嗪和前列地尔静脉滴注。3组患者连续治疗2周。检测治疗前后血糖、血脂,血清α1-微球蛋白和血清、尿β2-微球蛋白,血管指数和阻力指数。结果与治疗前比较,A组、B组和C组连续治疗2 w后,血清α1-微球蛋白、血清β2-微球蛋白和尿β2-微球蛋白水平均降低,差异具有统计学意义(P均<0.05)。与A组治疗后比较,C组治疗后血清α1-微球蛋白[(21.3±3.97)mg/L vs.(16.7±3.49)mg/L]、血清β2-微球蛋白[(3136.5±310)μg/L vs.(2557.6±275.8)μg/L]和尿β2-微球蛋白[(138.2±13.8)μg/L vs.(109.7±13.6)μg/L]水平均降低,差异具有显著统计学意义(P均<0.01)。与B组治疗后比较,C组治疗后血清α1-微球蛋白[(21.9±3.88)mg/L vs.(16.7±3.49)mg/L]、血清β2-微球蛋白[(3188.6±298.7)μg/L vs.(2557.6±275.8)μg/L]和尿β2-微球蛋白[(139.3±14.2)μg/L vs.(109.7±13.6)μg/L]水平均降低,差异具有显著统计学意义(P均<0.01)。与A组治疗后比较,C组治疗后血管指数[(31.3±7.07) vs.(35.7±7.26)]升高,阻力指数[(0.60±0.05) vs.(0.51±0.04)]降低,差异具有统计学意义(P均<0.05)。与B组治疗后比较,C组治疗后血管指数[(31.1±7.12) vs.(35.7±7.26)]升高,阻力指数[(0.61±0.05) vs.(0.51±0.04)]降低,差异具有统计学意义(P均<0.05)。结论丹参川芎嗪、前列地尔均能减轻高血压早期肾损害,两者联用,效果优于单独使用。
目的:探討丹參川芎嗪聯閤前列地爾對原髮性高血壓患者早期腎損害的療效。方法選擇2011年12月至2013年11月在肇慶醫專附屬醫院心內科住院的輕、中度原髮性高血壓伴早期腎損害患者120例,其中男性62例,女性58例,年齡33~78歲。所有患者隨機分為A組,B組,C組,每組40例。所有患者均予纈沙坦降壓治療,A組加用丹參川芎嗪註射液,B組加用前列地爾註射液,C組同時給予丹參川芎嗪和前列地爾靜脈滴註。3組患者連續治療2週。檢測治療前後血糖、血脂,血清α1-微毬蛋白和血清、尿β2-微毬蛋白,血管指數和阻力指數。結果與治療前比較,A組、B組和C組連續治療2 w後,血清α1-微毬蛋白、血清β2-微毬蛋白和尿β2-微毬蛋白水平均降低,差異具有統計學意義(P均<0.05)。與A組治療後比較,C組治療後血清α1-微毬蛋白[(21.3±3.97)mg/L vs.(16.7±3.49)mg/L]、血清β2-微毬蛋白[(3136.5±310)μg/L vs.(2557.6±275.8)μg/L]和尿β2-微毬蛋白[(138.2±13.8)μg/L vs.(109.7±13.6)μg/L]水平均降低,差異具有顯著統計學意義(P均<0.01)。與B組治療後比較,C組治療後血清α1-微毬蛋白[(21.9±3.88)mg/L vs.(16.7±3.49)mg/L]、血清β2-微毬蛋白[(3188.6±298.7)μg/L vs.(2557.6±275.8)μg/L]和尿β2-微毬蛋白[(139.3±14.2)μg/L vs.(109.7±13.6)μg/L]水平均降低,差異具有顯著統計學意義(P均<0.01)。與A組治療後比較,C組治療後血管指數[(31.3±7.07) vs.(35.7±7.26)]升高,阻力指數[(0.60±0.05) vs.(0.51±0.04)]降低,差異具有統計學意義(P均<0.05)。與B組治療後比較,C組治療後血管指數[(31.1±7.12) vs.(35.7±7.26)]升高,阻力指數[(0.61±0.05) vs.(0.51±0.04)]降低,差異具有統計學意義(P均<0.05)。結論丹參川芎嗪、前列地爾均能減輕高血壓早期腎損害,兩者聯用,效果優于單獨使用。
목적:탐토단삼천궁진연합전렬지이대원발성고혈압환자조기신손해적료효。방법선택2011년12월지2013년11월재조경의전부속의원심내과주원적경、중도원발성고혈압반조기신손해환자120례,기중남성62례,녀성58례,년령33~78세。소유환자수궤분위A조,B조,C조,매조40례。소유환자균여힐사탄강압치료,A조가용단삼천궁진주사액,B조가용전렬지이주사액,C조동시급여단삼천궁진화전렬지이정맥적주。3조환자련속치료2주。검측치료전후혈당、혈지,혈청α1-미구단백화혈청、뇨β2-미구단백,혈관지수화조력지수。결과여치료전비교,A조、B조화C조련속치료2 w후,혈청α1-미구단백、혈청β2-미구단백화뇨β2-미구단백수평균강저,차이구유통계학의의(P균<0.05)。여A조치료후비교,C조치료후혈청α1-미구단백[(21.3±3.97)mg/L vs.(16.7±3.49)mg/L]、혈청β2-미구단백[(3136.5±310)μg/L vs.(2557.6±275.8)μg/L]화뇨β2-미구단백[(138.2±13.8)μg/L vs.(109.7±13.6)μg/L]수평균강저,차이구유현저통계학의의(P균<0.01)。여B조치료후비교,C조치료후혈청α1-미구단백[(21.9±3.88)mg/L vs.(16.7±3.49)mg/L]、혈청β2-미구단백[(3188.6±298.7)μg/L vs.(2557.6±275.8)μg/L]화뇨β2-미구단백[(139.3±14.2)μg/L vs.(109.7±13.6)μg/L]수평균강저,차이구유현저통계학의의(P균<0.01)。여A조치료후비교,C조치료후혈관지수[(31.3±7.07) vs.(35.7±7.26)]승고,조력지수[(0.60±0.05) vs.(0.51±0.04)]강저,차이구유통계학의의(P균<0.05)。여B조치료후비교,C조치료후혈관지수[(31.1±7.12) vs.(35.7±7.26)]승고,조력지수[(0.61±0.05) vs.(0.51±0.04)]강저,차이구유통계학의의(P균<0.05)。결론단삼천궁진、전렬지이균능감경고혈압조기신손해,량자련용,효과우우단독사용。
Objective To investigate the curative effect of Danshen Chuanxiongqin Injection combining alprostadil on early renal damage in patients with primary hypertension. Methods The patients (n=120, male 62 and female 58, aged from 33 to 78) with mild or moderate primary hypertension and early renal damage were randomly divided into group A, group B and group C (each n=40). All patients were treated with valsartan, and group A was additionally given Danshen Chuanxiongqin Injection, group B, alprostadil injection and group C, Danshen Chuanxiongqin Injection and alprostadil injection for 2 w. The changes of blood glucose, blood fat,α1-microglobulin (α1MG) in serum,β2-microglobulin (β2MG) in serum and urine, vascular index and resistance index were detected before and after treatment. Results After treatment for 2 w,α1MG in serum andβ2MG in serum and urine decreased in 3 groups (all P<0.05). Compared with group A, serumα1MG [(21.3±3.97) mg/L vs. (16.7±3.49) mg/L], serumβ2MG [(3136.5±310)μg/L vs. (2557.6±275.8)μg/L] and urinaryβ2MG [(138.2± 13.8)μg/L vs. (109.7±13.6)μg/L, all P<0.01] all decreased in group C. Compared with group B, serumα1MG [(21.9±3.88) mg/L vs. (16.7±3.49) mg/L], serumβ2MG [(3188.6±298.7)μg/L vs. (2557.6±275.8)μg/L] and urinaryβ2MG [(139.3±14.2)μg/L vs. (109.7±13.6)μg/L, all P<0.01] all decreased in group C. Compared with group A, vascular index increased [(31.3±7.07) vs. (35.7±7.26)], and resistance index decreased [(0.60± 0.05) vs. (0.51±0.04), all P<0.05] in group C. Compared with group B, vascular index increased [(31.1±7.12) vs. (35.7±7.26)], and resistance index decreased [(0.61±0.05) vs. (0.51±0.04), all P<0.05] in group C. Conclusion Danshen Chuanxiongqin Injection and alprostadil all can relieve early renal damage in hypertensive patients, and combination of them will has better curative effect.